Richard V. Smith

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/5cfed8d0-7107-11ef-bcd0-1ffe957a876f.jpg

First Name

Richard

Last Name

Smith

NPI

1629149018

Faculty ID

5016

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Smith, an otolaryngologist (ear, nose and throat, or ENT, doctor) and head and neck surgeon, is actively involved in numerous research projects studying cancers of the head and neck. His research focuses is on identifying genetic and biologic aspects of such cancers that correlate with a patient&rsquo;s prognosis. His goal is to help determine the optimal treatment for an individual patient, to maximize their chance of cure and minimize treatment-related side effects. In addition, his clinical investigation has focused on developing new techniques in transoral surgery, a less invasive form of surgery through which the surgeon gains access through the mouth. At the same time, he seeks to assess the quality of life benefits for such treatments.</p>
<p>Dr. Smith&rsquo;s service to professional medical societies includes serving as president of the New York Head and Neck Society and president of the New York Laryngological Society.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Smith's areas of expertise include Head and Neck Cancer Surgery, Robotic Head and Neck Surgery, Thyroid and Parathyroid Surgery, Salivary Gland Surgery, Minimally Invasive Head and Neck Surgery. His research focus is on identifying genetic and biologic aspects of head and neck cancer which correlate with a patient’s prognosis, the goal of which is to help determine the optimal treatment for an individual patient to maximize their chance of cure and minimize treatment related side effects.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Smith&rsquo;s clinical focus is on head and neck surgery, including transoral robotic and laser surgery for throat and larynx cancer, salivary gland, thyroid and parathyroid surgery.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Smith's research focuses on genetic changes (and how these affect treatment), quality of life issues in head and neck cancer and surgical education and simulation.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p>Publications available through PubMed link</p>
<p>Textbooks</p>
<p><u>Complications in Otolaryngology-Head and Neck Surgery</u>, 2^nd Edition, eds. Eisele D, Smith RV. Elsevier, Philadelphia, 2008.</p>
<p><u>The Larynx</u>, eds. Fried MP, Ferlito A, Rinaldo A, Smith RV. Plural, San Diego. 2009.</p>

EMR ID

3919

Biography

<p>Richard V. Smith, MD, FACS, is Chair, Otorhinolaryngology-Head &amp; Neck Surgery, Professor, Otorhinolaryngology-Head &amp; Neck Surgery, Professor, Surgery and Professor, Pathology at Montefiore Einstein. Dr. Smith&rsquo;s clinical focus is on head and neck surgery, including transoral robotic and laser surgery for throat and larynx cancer, salivary gland, thyroid and parathyroid surgery.</p><p>After obtaining his Bachelor of Arts in 1984 at Middlebury College, Dr. Smith received his Doctor of Medicine at the University of Vermont College of Medicine in 1990. He completed an internship in surgery in 1991, followed by a residency in the Department of Otolaryngology-Head and Neck Surgery at Georgetown University Hospital, completed in 1995.</p><p>Dr. Smith's research focuses on genetic changes (and how these affect treatment), quality of life issues in head and neck cancer and surgical education and simulation. He is actively involved in numerous research projects studying cancers of the head and neck. His research focuses on identifying genetic and biological aspects of such cancers that correlate with a patient&rsquo;s prognosis. His goal is to help determine the optimal treatment for an individual patient, to maximize their chance of cure and minimize treatment-related side effects. In addition, his clinical investigation has focused on developing new techniques in transoral surgery, a less invasive form of surgery through which the surgeon gains access through the mouth. At the same time, he seeks to assess the quality of life benefits for such treatments. His work has been published in numerous journals, books, and reviews, and presented internationally at lectures and meetings.</p><p>Dr. Smith is board certified by the American Board of Otolaryngology and a member of many organizations, including the American Academy of Otolaryngology-Head and Neck Surgery, the American College of Surgeons and the American Head and Neck Society. He also served as president of the New York Head and Neck Society and president of the New York Laryngological Society. He is also focused on Continuing Professional Development and was the Education Coordinator for the American Academy of Otolaryngology-Head and Neck Surgery from 2015-2019.</p><p>From 2009 to 2022, Dr. Smith has been listed as one of New York's Best Doctors in New York Magazine, and from 2010 to 2022 he has been listed on New York Times Magazine's list of Super Doctors. He received the Children's Humanitarian Award from the Children's Tumor Foundation in 2007, has received the Distinguished Service Award from the American Academy of Otolaryngology-Head and Neck Surgery in 2010 and 2020, a Presidential Citation from the American Head and Neck Society in 2011 and the Academic Achievement Award from the University of Vermont College of Medicine in 2015. In 2021 the American Academy of Otolaryngology-Head and Neck Surgery honored Dr. Smith with their Board of Governors&rsquo; Practitioner Excellence Award, which recognizes an otolaryngologist that others wish to emulate and who is sought out by other physicians because of their personal and effective care.</p>

Is Open Scheduling

On

Nicole S. Nevadunsky

https://assets.montefioreeinstein.org/profiles/images/Nevadunsky_NIcole_MD_2x.jpg

First Name

Nicole

Last Name

Nevadunsky

NPI

1619131430

Faculty ID

11884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Comprehensive care of women with uterine, cervical, and vulvar cancers. &nbsp;Interests include minimally invasive and robotic techniques.&nbsp;</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Nicole Nevadunsky conducts translational research that enables her to deliver the highest quality care for her patients. She specializes in the prevention and treatment of gynecologic cancers. Recent clinical studies have evaluated palliative care in improving quality of life in patients with high risk primary or recurrent gynecologic malignancies; and physical activity interventions for endometrial cancer survivors.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5257

Is Open Scheduling

Off

Shalom Kalnicki

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/89820450-b883-11ee-8618-fda8dc77c52b.jpg

First Name

Shalom

Last Name

Kalnicki

NPI

1942381371

Faculty ID

9551

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Kalnicki, a radiation oncologist, focuses on new technologies in the radiation treatment of cancer. He was a pioneer in the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. Another area of interest is the use of stereotactic guidance in radiation treatment, specifically for stereotactic radiosurgery (SRS). All enhance precision of tumor targeting with radiation therapy, increasing dose to the tumor, while sparing surrounding normal tissues.<br />&nbsp;<br />Dr. Kalnicki's research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies. His clinical interests focus on head and neck, prostate, and breast cancers.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Radiation Oncology

Research Focus

An active researcher, Dr. Kalnicki is currently investigating innovative methods of radiation planning and delivery, including Intensity Modulated Radiation Therapy (IMRT), PET-CT fusion for radiation planning, 4-D treatment planning, target motion manage

Elsevier Profile

EMR ID

4214

Biography

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. He pioneered the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, stereotactic body radiation therapy (SBRT) and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p><p>Dr. Kalnicki earned his medical degree at the University of Sao Paulo Medical School in Sao Paulo, Brazil. He completed his residency and fellowship in radiotherapy at Montefiore and Albert Einstein College of Medicine. He came to Montefiore and Einstein from the University of Pittsburgh, School of Medicine, where he was Vice Chairman for Clinical Affairs and Director of Radiation Oncology at the University of Pittsburgh Cancer Institute. </p><p>Prior to joining the University of Pittsburgh Cancer Institute, Dr. Kalnicki served as Chairman of the Department of Radiation Oncology at Allegheny University of Health Sciences in Pittsburgh. He is a member of many prominent professional societies. He has authored numerous articles and abstracts during his career and is a recipient of several awards, including the Fellowship Award from the American College of Radiation Oncology.</p>

Is Open Scheduling

Off

Balazs Halmos

https://assets.montefioreeinstein.org/profiles/images/Halmos_Balazs_MD_2x.jpg

First Name

Balazs

Last Name

Halmos

NPI

1013933290

Faculty ID

14771

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Balazs Halmos, MD, MS was recruited in May 2015 to serve as Director of the Multidisciplinary Thoracic Oncology Program and Director of the Section of Thoracic Medical Oncology for Montefiore Health Systems. Dr. Halmos has also been appointed as the first Director of Clinical Cancer Genetics and Professor of Clinical Medicine at Einstein.</p>
<p>Dr. Halmos is an authority in the management of patients with malignancies of the thoracic cavity such as lung cancer, gastroesophageal cancer and thymoma. His research interests are focused on studies of targeted agents for the treatment of thoracic malignancies as well as translational studies aimed at different aspects of lung cancer biology such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation and targeted therapeutics. He will oversee the thoracic clinical trials program and spearhead the effort to develop guidelines for genetic testing for cancer patients of different anatomic sites to implement a personalized cancer medicine approach.</p>
<p>Dr. Halmos joined Montefiore and Einstein from Columbia University Medical Center, where he was Director of Thoracic Medical Oncology since 2009, Associate Professor of Medicine, and Chairman of the Cancer IRB. He completed a medical degree summa cum laude from Semmelweis University in Budapest, Hungary, an internal medicine residency at St.Luke&rsquo;s-Roosevelt Hospital/Columbia University, and a hematology/oncology fellowship program at Beth Israel Deaconess Medical Center/Harvard Medical School, where he also obtained a master of science in clinical sciences from Harvard Medical School. Since completion of his fellowship, he has been on the faculties at Harvard, Case Western Reserve University, and Columbia.</p>
<p>Dr. Halmos is the recipient of multiple awards from organizations such as the American Society of Clinical Oncology, American Association for Cancer Research, and American Cancer Society and serves as a permanent review board member for the American Cancer Society. He is board certified in internal medicine and medical oncology.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Halmos is an authority in the management of patients with malignancies of the thoracic cavity such as lung cancer, gastroensophageal cancer and thymoma. His research interests are focused on studies of targeted agents for the treatment of thoracic malignancies as well as translational studies aimed at different aspects of lung cancer biology such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation and targeted therapeutics. He oversees the thoracic clinical trials program and spearheads the effort to develop guidelines for genetic testing for cancer patients of different anatomic sites to implement a personalized cancer medicine approach.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Halmos is a thoracic medical oncologist focused on the management of patients with malignancies of the thoracic cavity, such as lung and gastroesophageal cancers as well as thymoma. He also oversees the thoracic clinical trials program of novel clinical studies at the Albert Einstein Cancer Center and is spearheading the effort to develop a molecular testing paradigm for cancer patients managed within the Montefiore Health System to facilitate a personalized cancer medicine approach throughout the health system.

Research Focus

Dr. Halmos&rsquo; research interests encompass clinical studies of experimental therapeutics, in particular studies of targeted agents for the treatment of thoracic malignancies as well as translational studies focused on different aspects of lung cancer biology, such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation and targeted therapeutics.

Elsevier Profile

EMR ID

33129

Biography

<p>Balazs Halmos, MD received his medical degree summa cum laude from Semmelweis University in Budapest, Hungary. He completed an internal medicine residency program at St.Luke&rsquo;s-Roosevelt Hospital/Columbia University in New York City followed by a hematology/oncology fellowship program at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Massaschuestts.</p><p>While in Dr. Halmos, also obtained an MS degree in Clinical Sciences from Harvard Medical School. Since completion of his fellowship, he has been a faculty member at Harvard, Case Western Reserve University and most recently an Associate Professor of Medicine at Columbia University Medical Center in New York. There he served as Director of Thoracic Oncology from 2009-2014 and was also Chair of the Cancer IRB.</p><p>Dr. Halmos also oversees the thoracic clinical trials program of novel clinical studies at the Montefiore Albert Einstein Cancer Center and is spearheading the effort to develop a molecular testing paradigm for cancer patients managed within the Montefiore to facilitate a personalized cancer medicine approach throughout the health system.</p><p>He is the recipient of multiple awards from prestigious organizations such as the American Society of Clinical Oncology, American Association for Cancer Research and the American Cancer Society, where he also serves as a permanent review board member. </p>

Is Open Scheduling

Off

Chandan Guha

https://assets.montefioreeinstein.org/profiles/images/physphoto/Guha_Chandan_MD_420x504.jpg

First Name

Chandan

Last Name

Guha

NPI

1093917924

Faculty ID

7020

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Exploring therapeutic potential of stem cell regeneration in the event of radiation insult </strong><br />Exposure to high doses of ionizing radiation in the event of therapeutic, accidental or intentional incident such as nuclear/radiological warfare can lead to debilitating injuries to multiple organs resulting in death within days depending on the amount of radiation dose and the quality of radiation. Unfortunately, there is not a single FDA-licensed drug approved against acute radiation injury.</p>
<p>Radiation damage to multiple organs often described as multiple organ dysfunction syndrome (MODS) or acute radiation syndrome (ARS) results from rapid depletion of radiosensitive cells, these cells are usually the stem or progenitor cells with high proliferative capacity; naturally, bone marrow stem cells (BMSC), and intestinal stem cells (ISC), which are extremely critical in maintaining a pool of peripheral blood cells and in maintaining villi for the absorption of nutrients are highly sensitive to radiation. One of the most efficient ways of rescuing MODS is to administer fresh cells that can repair, support and/or replace the damaged cells and repopulate the damaged tissue with healthy cells. The Rad-Stem Center for Medical Countermeasures against Radiation (RadStem CMCR) program at Einstein is developing stem cell-based therapies to treat acute radiation syndrome (ARS) that results from radiation injury.</p>
<p>Radiation-induced gastrointestinal syndrome (RIGS) results from a combination of direct damage to intestinal crypt and endothelial cells, and subsequent loss of the mucosal barrier leading to microbial infection, septic shock and systemic inflammatory response syndrome (SIRS). Currently, there is no treatment for RIGS in clinic. Irradiation induces apoptosis of crypt ISC, endothelial cells and enterocytes within hours. Acute loss of cells in situ requires rapid compensation of their functions and this is best achieved using cell replacement therapies. We are interested in exploring intestinal regenerative therapy with a combination of systemic administration of growth factors and cell replacement therapy to salvage Gl function post-radiation exposure. We are testing combinations of: a) intestinal stem cell growth factor, R-spondinl (R-spol), b) TLR ligands, and c) transplantation of bone marrow-derived endothelial progenitor cells (EPC) and mesenchymal stem cells (MSC) to restore IR-damaged ISC niche, protect against IR-induced cell death and provide growth signals for host ISC regeneration, thus providing protection and mitigation from RIGS.</p>
<p><strong>Preparative live irradiation for hepatocyte transplant in acute liver injury and cirrhosis </strong><br />Hepatocyte transplantation (HT) is a very attractive alternative to liver transplant in the treatment of both inherited and acquired liver diseases. However, benefits of this procedure are currently limited by the inability of the transplanted hepatocytes to proliferate in the host liver, and lack of a noninvasive method to evaluate the repopulation of transplanted hepatocytes in the liver. In order to develop a clinically feasible protocol for HT, we are exploring preparative hepatic irradiation (HIR) for liver repopulation (in place of liver transplant) to deplete host hepatocytes and permit preferential proliferation of the engrafted donor cells in response to hepatic mitotic stimuli.<strong> &nbsp;</strong>Our lab was the first one to demonstrate that preparative HIR and partial hepatectomy (PH), followed by HT results in the replacement of virtually all host hepatocytes by the transplanted non-irradiated hepatocytes in 12 weeks. We are interested in using inducible pluripotent stem cells (iPSC)- derived hepatocytes following highly focused irradiation of the damaged liver in place of a liver transplant. We are also interested in exploring non-invasive biomarkers to validate that the transplanted hepatocytes can efficiently replace host hepatocytes upon liver irradiation.</p>
<p><strong>Cancer Immunotherapy </strong><br />Radiation therapy (RT) has been used as a standard treatment modality for many solid tumors. While tumoricidal properties of RT are instrumental for standard clinical application, irradiated tumors can potentially serve as a source of tumor antigens <em>in vivo</em>, where dying tumor cells would release various tumor antigens slowly over time. Using different<em> in vitro</em> and <em>in vivo</em> tumor models we, and others, demonstrated that RT enhances oxidative stress, and augments the release of necessary activating signals for DC such as endogenous danger associated molecular pattern (DAMP) molecules from irradiated cells. These RT-mediated processes lead to an increase antigenecity of irradiated cells which augments antigen presentation leading to an effective anti-tumoral immune responses. However the underlying mechanism of this processes has still to be determined.</p>
<p>Over the last years we have been interested in designing novel tumor vaccines that amplify the tumor immune response using conventional and exploratory cancer therapies. In particular we are focusing on evaluating the immunogenic properties of radiation therapies and determine how immunotherapeutic molecules can synergize with RT in boosting immune cells cell function. We are also interested in exploring therapeutic effect of ultrasound therapy in the treatment of solid tumor. Our recent work on use of Listeria-based vaccine therapy in combination of RT shows that this strategy is more effective than RT alone.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Guha is a radiation oncologist who specializes in prostate, genitourinary, liver and GI malignancies, and radio surgery. His research interests include development of stem-cell based therapies to treat radiation-induced toxicity and prevent death in patients.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Immunomodulation of radiation therapy: Radiation-enhanced tumor vaccines</strong></p>
<ol>
<li>Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of Radiotherapy: New Paradigms. Radiat Res. 2014, Aug;182(2):123-5</li>
<li>Almo SC, Guha C. Considerations for Combined Immune Checkpoint Modulation and Radiation Treatment. Radiat Res. 2014, Aug;182(2):230-8</li>
<li>Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, Roy-Chowdhury J, Guha C. An Autologous In Situ Tumor Vaccination Approach for Hepatocellular Carcinoma. Flt3 Ligand Gene Transfer Increases Antitumor Effects of a Radio-Inducible Suicide Gene Therapy in an Ectopic Tumor Model. Radiat Res. 2014 Aug;182(2):201-10</li>
<li>Bernstein, Michael B; Garnett, Charlie T; Zhang, Huogang; Velcich, Anna; Wattenberg, Max M; Gameiro, Sofia R; Kalnicki, Shalom; Hodge, James W; Guha, Chandan. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer biotherapy &amp; radiopharmaceuticals, 2014 May; 29 (4):153-61</li>
<li>Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res. 2013 Nov;1(5):280-4</li>
<li>Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One. 2013 Jul 24;8(7)</li>
<li>Zhang, Huagang; Liu, Laibin; Yu, Dong; Kandimalla, Ekambar R; Sun, Hui Bin; Agrawal, Sudhir; Guha, Chandan. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PloS one, 2012; 7 (5)</li>
<li>Hannan, Raquibul; Zhang, Huagang; Wallecha, Anu; Singh, Reshma; Liu, Laibin; Cohen, Patrice; Alfieri, Alan; Rothman, John; Guha, Chandan. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer immunology, immunotherapy: CII, 2012 Dec; 61 (12):2227-38</li>
</ol>
<p><strong>Stem cell based therapy for radiation injury</strong></p>
<ol>
<li>Benderitter, Marc; Caviggioli, Fabio; Chapel, Alain; Coppes, Robert P; Guha, Chandan; Klinger, Marco; Malard, Olivier; Stewart, Fiona; Tamarat, Radia; Luijk, Peter Van; Limoli, Charles L. Stem Cell Therapies for the Treatment of Radiation-Induced Normal Tissue Side Effects. Antioxidants &amp; redox signaling, 2014, Jul 10;21(2):338-55</li>
<li>Zachman, Derek K; Leon, Ronald P; Das, Prerna; Goldman, Devorah C; Hamlin, Kimberly L; Guha, Chandan; Fleming, William H. Endothelial cells mitigate DNA damage and promote the regeneration of hematopoietic stem cells after radiation injury. Stem cell research, 2013 Nov; 11 (3):1013-21</li>
<li>Saha, Subhrajit; Bhanja, Payel; Liu, Laibin; Alfieri, Alan A; Yu, Dong; Kandimalla, Ekambar R; Agrawal, Sudhir; Guha, Chandan, &lsquo;TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome&rsquo;; PloS one, 2012; 7 (1)</li>
<li>Saha, Subhrajit; Bhanja, Payel; Kabarriti, Rafi; Liu, Laibin; Alfieri, Alan A; Guha, Chandan,. Bone marrow stromal cell transplantation mitigates radiation-induced gastrointestinal syndrome in mice. PloS one, 2011; 6 (9)</li>
<li>Bhanja P, Saha S, Kabarriti R, Liu L, Roy-Chowdhury N, Roy-Chowdhury J, Sellers RS, Alfieri AA, Guha C. Protective role of R-spondin1, an intestinal stem cell growth factor, against radiation-induced gastrointestinal syndrome in mice. PLoS One. 2009 Nov 24;4(11)</li>
</ol>
<p><strong>Preparative irradiation to facilitate liver cell repopulation and stem cell engraftment <em>in vivo</em></strong></p>
<ol>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics, 2014 Jul 15; 89 (4):786-803</li>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics. 2014 Jul 15; 89 (4):786-803</li>
<li>Yannam, Govardhana Rao; Han, Bing; Setoyama, Kentaro; Yamamoto, Toshiyuki; Ito, Ryotaro; Brooks, Jenna M; Guzman-Lepe, Jorge; Galambos, Csaba; Fong, Jason V; Deutsch, Melvin; Quader, Mubina A; Yamanouchi, Kosho; Kabarriti, Rafi; Mehta, Keyur; Soto-Gutierrez, Alejandro; Roy-Chowdhury, Jayanta; Locker, Joseph; Abe, Michio; Enke, Charles A; Baranowska-Kortylewicz, Janina; Solberg, Timothy D; Guha, Chandan; Fox, Ira J. A nonhuman primate model of human radiation-induced venocclusive liver disease and hepatocyte injury. International journal of radiation oncology, biology, physics, 2014 Feb 1; 88 (2):404-11</li>
<li>Miyazaki, Kensuke; Yamanouchi, Kosho; Sakai, Yusuke; Yamaguchi, Izumi; Takatsuki, Mitsuhisa; Kuroki, Tamotsu; Guha, Chandan; Eguchi, Susumu, &lsquo;Construction of liver tissue in&yacute;&yacute;vivo with preparative partial hepatic irradiation and growth stimulus: investigations of less invasive techniques and progenitor cells&rsquo;; The Journal of surgical research. 2013 Dec; 185 (2):889-95</li>
<li>Puppi, Juliana; Strom, Stephen C; Hughes, Robin D; Bansal, Sanjay; Castell, Jose V; Dagher, Ibrahim; Ellis, Ewa C S; Nowak, Greg; Ericzon, Bo-Goran; Fox, Ira J; Gomez-Lechon, M Jose; Guha, Chandan; Gupta, Sanjeev; Mitry, Ragai R; Ohashi, Kazuo; Ott, Michael; Reid, Lola M; Roy-Chowdhury, Jayanta; Sokal, Etienne; Weber, Anne; Dhawan, Anil, &lsquo;Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London&rsquo;; Cell transplantation. 2012; 21 (1):1-10</li>
<li>Zhou, Hongchao; Dong, Xinyuan; Kabarriti, Rafi; Chen, Yong; Avsar, Yesim; Wang, Xia; Ding, Jianqiang; Liu, Laibin; Fox, Ira J; Roy-Chowdhury, Jayanta; Roy-Chowdhury, Namita; Guha, Chandan. Single liver lobe repopulation with wildtype hepatocytes using regional hepatic irradiation cures jaundice in Gunn rats. PloS one. 2012; 7 (10)</li>
<li>Ding, Jianqiang; Yannam, Govardhana R; Roy-Chowdhury, Namita; Hidvegi, Tunda; Basma, Hesham; Rennard, Stephen I; Wong, Ronald J; Avsar, Yesim; Guha, Chandan; Perlmutter, David H; Fox, Ira J; Roy-Chowdhury, Jayanta. Spontaneous hepatic repopulation in transgenic mice expressing mutant human &yacute;&yacute;1-antitrypsin by wild-type donor hepatocytes. The Journal of clinical investigation, 2011 May; 121 (5):1930-4</li>
<li>Soltys, Kyle A; Soto-Gutierrez, Alejandro; Nagaya, Masaki; Baskin, Kevin M; Deutsch, Melvin; Ito, Ryotaro; Shneider, Benjamin L; Squires, Robert; Vockley, Jerry; Guha, Chandan; Roy-Chowdhury, Jayanta; Strom, Stephen C; Platt, Jeffrey L; Fox, Ira J. Barriers to the successful treatment of liver disease by hepatocyte transplantation. Journal of hepatology, 2010 Oct; 53 (4):769-74</li>
<li>Dawson, Laura A; Guha, Chandan. Hepatocellular carcinoma: radiation therapy. Cancer journal (Sudbury, Mass.), 2008 Mar-Apr; 14 (2):111-6</li>
<li>Agoni, Lorenzo; Basu, Indranil; Gupta, Seema; Alfieri, Alan; Gambino, Angela; Goldberg, Gary L; Reddy, E Premkumar; Guha, Chandan. Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. International journal of radiation oncology, biology, physics, 2014 Apr 1; 88 (5):1180-7</li>
</ol>

EMR ID

4049

Is Open Scheduling

Off

Sheldon M. Feldman

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/8b39c6a0-c3d2-11eb-9ea2-7374238588d1.jpg

First Name

Sheldon

Last Name

Feldman

NPI

1942283742

Faculty ID

8553

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Feldman leads the breast surgery and breast surgical oncology program at Montefiore. Since 2003, he has been recognized annually as one of New York Metro Area's "Top Doctors" and since 2004, he has also been included in the annual "Guide to America's Top Surgeons."

Dr. Feldman is a recognized leader in the development of innovative minimally invasive techniques to diagnose breast cancer. He also leads extensive research into the causes of breast cancer with the goal of being able to diagnose earlier and more effectively.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>The development of innovative, minimally invasive techniques to diagnose breast cancer.</p>

Research Focus

<p>Dr. Feldman has led extensive research into the causes of breast cancer with the goal of being able to diagnose earlier and more effectively.</p>

Elsevier Profile

EMR ID

21947

Biography

<p>Sheldon Marc Feldman, MD, is Chief, Breast Surgery and Breast Surgical Oncology, Professor, Surgery and Director, Breast Cancer Services at Montefiore Einstein. His clinical focus includes breast cancer, oncoplastic surgery with an emphasis on optimizing breast conservation, nipple-sparing mastectomy, minimally invasive diagnosis and treatment, intraoperative radiation, targeted tumor ablation, lymphedema prevention, and complementary integrative holistic care with an emphasis on physician-patient communication.</p><p>In 1971, Dr. Feldman received his Bachelor of Science in Biology and Psychology from State University of New York at Stony Brook. Following this, he attended the New York University Medical School where he received his Doctor of Medicine in 1975. He began his postgraduate training at NYU Medical Center, Bellevue Hospital in 1975 and spent 5 years completing an internship and residency in Surgery. He became Executive Chief Surgical Resident in 1980. Dr. Feldman then trained at Newark Beth Israel Medical Center, where he completed a fellowship in Peripheral Vascular Surgery in 1981.</p><p>Extending his clinical focus, Dr. Feldman focuses his research on targeted tumor ablation, intraoperative margin assessment, novel surgical techniques to minimize lymphedema risk, intraductal approach to breast cancer&ndash;evaluating biomarkers in nipple aspirate fluid (NAF) and intraductal diagnosis and therapy, nonsurgical treatment of ductal carcinoma, and breast cancer prevention. He has been a principal investigator on multiple research projects and has given lectures both nationally and internationally. Dr. Feldman&rsquo;s work has been presented in over 100 peer-reviewed publications.</p><p>From 2008 to 2015, he was named a New York Super Doctor in the New York Times. He was President of the American Society of Breast Surgeons from 2016 to 2017, and he is currently president of the New York Metropolitan Breast Group.</p><p>Dr. Feldman is board certified by the American Board of Surgery, and he is a fellow of the American College of Surgeons. He is also a member of numerous professional societies, including the American Society of Breast Surgeons, the Society of Surgical Oncology, the American Society of Clinical Oncology and the International Society of Lymphology.</p>

Is Open Scheduling

Off

Fernando J. Camacho

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/13e40740-3407-11ed-a217-973a6f37f311.jpg

First Name

Fernando

Last Name

Camacho

NPI

1427095785

Faculty ID

3840

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Camacho, is an accomplished medical oncologist with more than 30 years of experience serving the Bronx. He specializes in addressing the barriers that prevent oncology and benign hematology patients and families from accessing quality health care. The mission of the Community Oncology program is to provide access to preventative and state of the art cancer care and research through education, community outreach, physician engagement, and he is also is fluent in Spanish.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3218

Biography

<p>Fernando J. Camacho, MD, is Assistant Professor, Oncology & Hematology at Montefiore Einstein. He has over 30 years of experience in community oncology and is the former Director of Community Oncology at Montefiore Einstein Center for Cancer Care. This program was established to increase access to preventative and cutting-edge cancer care and research to Bronx and Westchester patients and families and enhance visibility of the Center for Cancer Care through education, outreach and community engagement.</p><p>After earning his Doctor of Medicine in 1973 from the State University of New York at Buffalo, Dr. Camacho completed an internal medicine internship and residency in 1976 at Montefiore Einstein, followed by a hematology fellowship which he completed in 1977. He then completed medical oncology and immunology fellowships at Memorial Sloan Kettering Cancer Institute in 1979.</p><p>Dr. Camacho was the founding partner of a private community-based medical oncology practice with 5 physicians at two sites, providing in-patient consultations at hospitals affiliated with The New York City Research and Improvement Networking Group, which includes Montefiore Einstein and St. Joseph&rsquo;s Medical Center in Yonkers. </p><p>Dr. Camacho belongs to several medical organizations, most prominently being a member of the American Society of Medical Oncology for over 42 years. In 2007 he was honored with the Great Mentor in Medicine Award for inspiring minority students to succeed in the health professions. In 2021, he was recognized as Man of the Year by SHARE Cancer Support Group of New York for his support of women with cancer. Dr. Camacho has also been recognized on numerous occasions by Castle Connolly Medical LTD as a New York Metro Top Doctor.</p>

Is Open Scheduling

Off

Robert D. Burk

https://assets.montefioreeinstein.org/profiles/images/Burk_Robert_MD_2x.jpg

First Name

Robert

Last Name

Burk

NPI

1639255904

Faculty ID

8221

CMO Specialties

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>The main focus of the Burk laboratory is to utilize population-based longitudinal studies from large epidemiological cohorts including those with and without HIV to study the dynamics of host-microbe interactions. These include HPV and development of cancer, and the human microbiome and disease outcomes (cancer, infectious diseases, cardiovascular disease, diabetes, obesity, aging).</p>
<p>To understand complex ecological community of bacteria, fungi, viruses and other organisms and how that might interact for disease outcomes.&nbsp; These studies are built on understanding the application of laboratory tests to population-based studies. They employ NGS and state of the art bioinformatics.</p>
<p>Other interests of the lab include the genetics of complex human disease (prostate cancer, excessive sweating) using large case-control clinical collections of genomic DNAs with candidate gene sequencing; and, the cell biology of VHL and its role in primary cilia formation and activity and its disruption in renal cancer.</p>
<p>The lab is dedicated to creating a warm environment based on collaborative science and teamwork.&nbsp; Our mission is to facilitate each individual reaching his or her potential through learning, experimentation and sharing in the pursuit of knowledge to promote human health and development.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<div>Dr. Burk is an authority on the genomics and evolution of human papillomaviruses (HPV), which cause nearly all cases of cervical cancer. His team was the first to report, in the <em>New England Journal of Medicine</em>, that the vast majority of HPV infections in young women are short-lived and don&rsquo;t require treatment. More recently, his lab is utilizing Next-Gen sequencing to study papillomavirus genomics and methylation of the viral genome. His lab utilized this new technology to identify HPV16 and beta- and gamma-HPVs associated with head and neck squamous cell cancers (HNSCCs).<br /><br /></div>
<div>Dr. Burk is also currently investigating the role of the human microbiome and cervical HPV natural history. He is a co-PI on a grant with Drs. Kaplan and Rob Knight (UCSD) studying the human gut microbiome and obesity and diabetes. Dr. Burk&rsquo;s lab has pioneered translational studies of the human microbiome by developing home collection kits that have been used to collect over 5,000 samples.<br /><br /></div>
<div>Dr. Burk was elected in 2015 as a fellow of the American Association for the Advancement of Science (AAAS).</div>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

Lab Website Link

Selected Publications

<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">(out of 503 published papers; google h-index 126)</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;"><span style="font-size: 12pt; text-indent: -27pt; font-family: Arial, sans-serif;">Gradissimo A, Clarke MA, Xue X, Castle PE, Raine-Bennett TR, Schiffman M, Wentzensen N, Strickler HD, Burk RD. A Novel HPV/Host DNA Methylation-Score and Detection of Cervical Adenocarcinoma. J Natl Cancer Inst. 2023. Epub 2023/07/19. doi: 10.1093/jnci/djad134. PMID: 37467068; </span><span style="font-size: 12pt; text-indent: -27pt; font-family: Arial, sans-serif; color: #191919;">PMC1069984</span><span style="font-size: 12pt; text-indent: -27pt; font-family: Arial, sans-serif;">.</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;"><span style="font-size: 12pt; font-family: Arial, sans-serif; color: #242424; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Usyk M, Peters B, Karthikeyan S, McDonald D, Sollecito C, Vazquez-Baeza Y, Shaffer J, Gellman M, Talavera G, Daviglus M, Thyagarajan B, K</span><span style="font-size: 12pt; font-family: Arial, sans-serif; color: #242424; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">night R, Qi Q, Kaplan RC, and Burk, R.D. Comprehensive Evaluation of Shotgun Metagenomics, </span><span style="font-size: 12pt; font-family: Arial, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Amplicon Sequencing and Harmonization of These Platforms for Epidemiological Studies. Cell Report Methods </span><span style="font-size: 12pt; font-family: Arial, sans-serif;">2023 Jan 23;3(1):100391. eCollection 2023 Jan 23. PMID:&nbsp;36814836; PMC9939430</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;"><span style="font-family: Arial, sans-serif; font-size: 12pt;">Schiffman M, Mirabello L, Egemen D, Befano B, Xiao Y, Wentzensen N, Raine-Bennett T, Nayar R, Cheung LC, Rositch A, Beaty T, Perkins RB, de Sanjose S, Lorey T, Castle PE, Burk RD. The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma. Gynecol Oncol. 2023;174:253-61. Epub 2023/05/27. doi: 10.1016/j.ygyno.2023.05.011. PMID: 37243996</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;"><span style="font-family: Arial, sans-serif; font-size: 12pt;">Burk RD, Mirabello L, DeSalle R. Distinguishing Genetic Drift from Selection in Papillomavirus Evolution. Viruses. 2023;15(8). Epub 2023/08/26. doi: 10.3390/v15081631. PMID: 37631973; PMC10458755.</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">Usyk M, Schlecht NF, Pickering S, Williams L, Sollecito CC, Gradissimo A, Porras C, Safaeian M, Pinto L, Herrero R, Strickler HD, Viswanathan S, Nucci-Sack A, Diaz A, Burk RD.<em>molBV</em>reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. Nat Commun. 2022;13(1):233. Epub 2022/01/13. doi: 10.1038/s41467-021-27628-3. PMID: 35017496;&nbsp;PMC8752746.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">Schlecht NF, Diaz A, Nucci-Sack A, Shyhalla K, Shankar V, Guillot M, Hollman D, Strickler HD, Burk RD. Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine. JAMA Netw Open. 2021 Aug 2;4(8):e2121893. doi: 10.1001/jamanetworkopen.2021.21893. PMID: 34424304; PMC8383132.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">Gressel GM, Usyk M, Frimer M, Kuo DYS, Burk RD. Characterization of the endometrial, cervicovaginal and anorectal microbiota in post-menopausal women with endometrioid and serous endometrial cancers. PLoS One. 2021 Nov 5;16(11):e0259188. doi: 10.1371/journal.pone.0259188. PMID: 34739493; PMC8570463.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">Chen Z, Utro F, Platt D, DeSalle R, Parida L, Chan PKS, Burk RD. K-Mer Analyses Reveal Different Evolutionary Histories of Alpha, Beta, and Gamma Papillomaviruses. Int J Mol Sci. 2021 Sep 6;22(17):9657. doi: 10.3390/ijms22179657. PMID: 34502564; PMC8432194.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">Kurilshikov,&nbsp;^&nbsp;A. . . . Burk, R.D. . . . Zhernakova, A. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat. Genet. 53: 156-165, 2021. doi: 10.1038/s41588-020-00763-1; PMID: 33462485;&nbsp;PMC8515199.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;"><span class="MsoHyperlink" style="color: blue; text-decoration: underline;"><span style="color: windowtext; text-decoration: none;">&nbsp;</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">Chen, Z., DeSalle, R., Schiffman, M., Herrero, R., Wood, C.E., Ruiz, J.C., Clifford, G.M., Chan, P.K.S. and Burk, R.D.&nbsp;&nbsp;Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. PLoS Pathog. 2018, 14(11):&nbsp;e1007352.&nbsp;PMID: 30383862; PMC6211759.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Arial;">Mirabello. L., Yeager, M., Yu, K., Clifford, G.M., Xiao, Y., Zhu, B., Cullen, M., Boland, J.F., Wentzensen, N., Nelson, C.W., Raine-Bennett, T., Chen, Z., Bass, S., Song, L., Yang, Q., Steinberg, M., Burdett, L., Dean, M.,&nbsp;Roberson, D., Mitchell, J., Lorey, T., Franceschi, S., Castle, P.E., Walker, J., Zuna, R., Kreimer, A.R., Beachler, D.C., Hildesheim, A., Gonzalez, P., Porras, C., Burk, R.D.<strong>* (co-last author)</strong>, Schiffman, M.<strong>*</strong>HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell. 2017 Sep 7;170(6):1164-1174.PMID: 28886384;&nbsp;PMC5674785</p>

EMR ID

3213

Biography

<p>Robert D. Burk, MD, is an attending physician at the Children&rsquo;s Hospital at Montefiore Einstein. He is Professor and Vice Chair, Translational Research, Pediatrics, Genetic Medicine, and Professor of Microbiology & Immunology; Epidemiology & Population Health; and Obstetrics, Gynecology & Women&rsquo;s Health at our Albert Einstein College of Medicine. Dr. Burk&rsquo;s clinical focus centers on cancer genetics and inherited cancer risk.</p><p>After earning his Doctor of Medicine at George Washington University School of Medicine in 1976, Dr. Burk completed a surgical internship at the University of California, San Francisco, in 1977. He remained at this institution to complete his pediatric residency in 1980, followed by a medical genetics fellowship at The Johns Hopkins University School of Medicine in 1983. He then became a Senior Research Fellow in molecular virology and hepatology at the Albert Einstein College of Medicine until 1984.</p><p>Dr. Burk&rsquo;s research focuses on human papillomavirus (HPV) genomics and its association with cancer and human microbiome studies, investigating the role of the human microbiome in health through large epidemiological studies. His work has been published in numerous peer-reviewed journals and shared through community presentations, media appearances, invited lectures, review articles and book chapters. He is a reviewer for many scientific journals, including the <em>New England Journal of Medicine</em><em>, Hepatology</em> and the <em>Journal of Virology</em>, among others.</p><p>Dr. Burk is a Diplomate of the National Board of Medical Examiners, the American Board of Pediatrics and the American Board of Medical Genetics as a Clinical Geneticist. He is or has been a member of several professional organizations, including the American Society for Microbiology, the American Society of Human Genetics and the Society for Pediatric Research, among others. In 2013, Dr. Burk received the Honorary Alumnus Award and the Saul R. Korey Award in Translational Science & Medicine from the Albert Einstein College of Medicine. In 2015, he became an Elected Fellow of the American Association for the Advancement of Science.</p>

Is Open Scheduling

Off

Jesus D. Anampa Mesias

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f27dbf80-2ee1-11ed-bcda-4d15024a9ee0.jpg

First Name

Jesus

Last Name

Anampa Mesias

NPI

1356590772

Faculty ID

14446

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Jesus Anampa is an Associate Professor of Medicine in the Department of Medical Oncology at Albert Einstein College of Medicine/ Montefiore Medical Center. Dr. Anampa is the Clinical Research Leader for Breast Oncology at Montefiore Medical Center and The Phase I Liaison for Breast Oncology.</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">A native of Peru, Dr. Anampa finished medical school at Universidad Peruana Cayetano Heredia in Lima, Peru, and successfully finished Internal Medicine Residency at Rochester General Hospital in Rochester, NY. Dr. Anampa initially joined Albert Einstein College of Medicine/Montefiore Medical Center to complete his fellowship in hematology/oncology and then joined our medical oncology faculty team at AECOM/MMC. In 2018, he obtained a Master&rsquo;s of Science degree &ldquo;with distinction&rdquo; in clinical research from Albert Einstein College of Medicine. Dr. Anampa is a practicing physician who specializes in breast medical oncology and clinical &amp; translational cancer research.&nbsp;</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p><strong><u><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Tumor MicroEnvironment of Metastasis</span></u></strong><u></u></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa is currently working with the tumor microenvironment (TME) program at Albert Einstein College of Medicine, which is a nationwide well-recognized program, lead by Dr. John Condeelis, evaluating new mechanisms of cancer intravasation and dissemination. Dr. Anampa plays an important role in translating bench-to-bedside and bedside-to-bench research in our TME program, and currently, he is working on the Tumor microenvironment of metastasis (TMEM) and its significance as a biomarker in breast cancer. Dr. Anampa is the principal investigator of a novel phase I trial targeting the tumor microenvironment to prevent metastasis. In addition, Dr. Anampa is leading a clinical trial to validate a novel imaging technique to identify metastasis doorways (TMEM) in vivo using MRI in patients with breast cancer.</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;"><a href="https://clinicaltrials.gov/ct2/show/NCT03694756">https://clinicaltrials…;
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;"><a href="https://clinicaltrials.gov/ct2/show/NCT02824575">https://clinicaltrials…;
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p><strong><u><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Breast Cancer and Obesity</span></u></strong><u></u></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa is working with the diabetes center at Albert Einstein to identify pathways associated with obesity and breast cancer. Preclinical studies at our institution have demonstrated that the CDK4/6-Rb pathway is affected in diet-induced obesity in mouse models. Dr. Anampa is leading a clinical trial that assesses the effect of CDK 4/6 inhibitors on body composition in patients with metastatic breast cancer.</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;"><a href="https://clinicaltrials.gov/ct2/show/NCT03697577">https://clinicaltrials…;
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p><strong><u><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Clinical/Translational Research Leadership</span></u></strong><u></u></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa is The Clinical Research Leader for Breast Oncology at Montefiore Medical Center/AECOM and he serves as local principal investigator for several Phase I, II, and III trials. In addition, Dr. Anampa is also a member of the Protocol Review and monitoring committee at Montefiore Medical Center/AECOM.</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa serves as the Montefiore Principal Investigator for the Translational Breast Cancer Research symposium (TBCRC) and the (I-Spy2)</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa is a native Spanish-speaker and has an innate passion for breast cancer research, with an ultimate goal to expand breast cancer therapeutic options and improve breast cancer outcomes. Dr. Anampa is also interested in breast cancer research and is always eager to participate in community activities related to breast cancer.</span></p>
<p>&nbsp;</p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">During his free time, Dr. Anampa enjoys mountain biking and soccer.</span></p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Anampa is a breast medical oncologist and a member of the Tumor Microenvironment and Metastasis (TMEM) research program at Albert Einstein College of Medicine, which focuses on targeting the tumor microenvironment as a mechanism to prevent the spread of breast cancer.
He is fluent in Spanish and enjoys participating in bilingual community activities about cancer prevention and treatment in the Bronx.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Breast cancer, medical oncology, clinical trials

Research Focus

Tumor micro-environment of metastasis and breast cancer; breast cancer immunology, new mechanisms of metastasis, cancer among minorities, breast cancer risk and outcomes among women with HIV

Elsevier Profile

EMR ID

56774

Biography

<p>Jesus Anampa Mesias, MD is a medical oncologist at Montefiore Einstein Comprehensive Cancer Center and a member of its Cancer Therapeutics Research Program focused on identifying new treatment targets and novel cancer therapeutics. He is fluent in Spanish and enjoys participating in bilingual community activities about cancer prevention and treatment in our community.</p><p>Dr. Anampa Mesias received his medical degree from the Universidad Peruana Cayetano Heredia in Lima, Peru, completed his residency in internal medicine at Rochester General Hospital in Rochester, NY, and completed a medical oncology/clinical hematology fellowship at Montefiore Medical Center. He remained at Albert Einstein as a research fellow before joining the medical oncology team at Montefiore.</p><p> </p>

Is Open Scheduling

Off